 |
 |
I am enrolled in a Phase 111 Clinical Trial of the above referenced drug which if effective, could prove to be neuroprotective against Parkinson's disease as well as effective in 'rescuing' injured dopamine nerve cells and promoting their survival. The study is still recruiting volunteers to participate from their home with scheduled visits to the study office in Philadelphia. I am from Norwalk, CT. and Have met people enrolled from 'Florida, California and Louisiana. Aside from two, in-person evaluations, applicants must have been on a stable meds regime for three months prior to evaluation and remain on an unchanged regime for the first six months of the study. The study is double blind, placebo controlled, with patients to receive the actual drug randomly chosen. The initial period is 6 months and those electing to continue thereafter are guaranteed to receive 2 years of the real (not placebo) drug. Two consecutive years if the first 6 months were placebo and another year and a half if the first six months were actual drug. Evaluation is threefold. Each participant self evaluates on each visit to Philadelphia; Similarly, two Drs'. conducting the study perform evaluations on each visit; and every six months, a SPECT scan is read. In simple lay terms (all I'm capable of), this machine counts the neurons in the brain so once a baseline is established, the results of these tests should indicate disease progress or lack thereof. I believe this SPECT scan is also under test simultaneous with the drug test. So if anyone's appetite is whetted, call the study administrators (excuse me ladies if I have your titles wrong) Stephanie Ferraro and Judy Hillman at 215-955-8700. The study is being run by Jay S. Schneider, Ph.D., Professor Depts. of Pathology, Anatomy and Cell Biology, and Neurology at Thomas Jefferson University Paul H. Lauer